Novavax’s updated COVID-19 vaccine receives emergency use authorization in the Republic of Korea; the EU, US and the World Health Organization previously authorized the vaccine for use

Sample article from our Government & Public Policy

November 29, 2023 (press release) –

Novavax’s partner, SK bioscience,today announced that Novavax’s updated COVID-19 vaccine (NVX-CoV2601) has received Emergency Use Authorization from the Ministry of Food and Drug Safety in the Republic of Korea.Doses are available in market for use this vaccination season.InSouth Korea, SK bioscience and Novavax have a licensing agreement where SK bioscience has exclusive commercial rights to Novavax’s updated COVID-19 vaccine. 

Novavax’s updated COVID-19 vaccine is also authorized in the U.S.,the European Union and by the World Health Organization,and is under review in other markets. 

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

More from our Government & Public Policy Coverage
See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order government & public policy coverage for our clients. Contact us for a free consultation.

Sectors

Sectors

Channels

Channels

Consumer Markerts

Consumer Markets

Business Drivers

Business Drivers

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Latest Public Posts

Useful Links

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

contact@industryintel.com
www.industryintel.com

About Cookies On This Site

This website stores cookies on your computer. These cookies are used to improve your website experience and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our Privacy Policy. We won't track your information when you visit our site. But in order to comply with your preferences, we'll have to use just one tiny cookie so that you're not asked to make this choice again.